Question normal

Most guidelines recommend metformin monotherapy for newly diagnosed T2D patients who have not compelling indications for other interventions. However, some expert recommend starting combination therapy irrespective of A1C level that consisting of 1) metformin, 2) TZD, GLP-1 analog, and 4) SGLT2-i to target the complex and multiple underlying abnormalities in T2D. (see: Diabetes 2009 Apr; 58(4): 773-795.)

Where our expert and panelists stand from this recommendation and viewpoint?